Isolation of Enterococcus faecium NM113, Enterococcus faecium NM213 and Lactobacillus casei NM512 as novel probiotics with immunomodulatory properties

• Published in: Microbiology and immunology 2014-10, Vol.58 (10), p.559-569
• Main Authors: Mansour, Nahla M., Heine, Holger, Abdou, Sania M., Shenana, Mohamed E., Zakaria, Mohamed K., El-Diwany, Ahmed
• Format: Article
• Language: English
• Subjects: Allergy; Antimicrobial agents; Bacteriology; Cylas; Enterococcus; Enterococcus faecium; Enterococcus faecium - chemistry; Enterococcus faecium - genetics; Enterococcus faecium - immunology; Enterococcus faecium - isolation & purification; Feces - microbiology; Humans; Hydrophobic and Hydrophilic Interactions; Immunologic Factors - chemistry; Immunologic Factors - genetics; Immunologic Factors - immunology; Immunologic Factors - isolation & purification; Immunomodulation; Infant; Infant, Newborn; Interleukin-12 - immunology; lactic acid bacteria; Lactobacillus casei; Lactobacillus casei - chemistry; Lactobacillus casei - genetics; Lactobacillus casei - immunology; Lactobacillus casei - isolation & purification; Lactococcus lactis; Monocytes - immunology; Monocytes - microbiology; Probiotics; Probiotics - classification; Probiotics - isolation & purification
• ISSN: 0385-5600; 1348-0421
• DOI: 10.1111/1348-0421.12187

Probiotics, defined as living bacteria that are beneficial for human health, mainly function through their immunomodulatory abilities. Hence, these microorganisms have proven successful for treating diseases resulting from immune deregulation. The aim of this study was to find novel candidates to improve on and complement current probiotic treatment strategies. Of 60 lactic acid bacterial strains that were isolated from fecal samples of healthy, full‐term, breast‐fed infants, three were chosen because of their ability to activate human immune cells. These candidates were then tested with regard to immunomodulatory properties, antimicrobial effects on pathogens, required pharmacological properties and their safety profiles. To identify the immunomodulatory structures of the selected isolates, activation of specific innate immune receptors was studied. The three candidates for probiotic treatment were assigned Enterococcus faecium NM113, Enterococcus faecium NM213 and Lactobacillus casei NM512. Compared with the established allergy‐protective strain Lactococcus lactis G121, these isolates induced release of similar amounts of IL‐12, a potent inducer of T helper 1 cells. In addition, all three neonatal isolates had antimicrobial activity against pathogens. Analysis of pharmacological suitability showed high tolerance of low pH, bile salts and pancreatic enzymes. In terms of safe application in humans, the isolates were sensitive to three antibiotics (chloramphenicol, tetracycline and erythromycin). In addition, the Enterococcus isolates were free from the four major virulence genes (cylA, agg, efaAfs and ccf). Moreover, the isolates strongly activated Toll‐like receptor 2, which suggests lipopeptides as their active immunomodulatory structure. Thus, three novel bacterial strains with great potential as probiotic candidates and promising immunomodulatory properties have here been identified and characterized.